The mission of the Georgetown University Memory Disorders Program is to prevent and treat Alzheimer’s disease and related dementias by conducting innovative research, educating and training healthcare professionals and the public on research advances, and offering state-of-the-art clinical care.
Treatment with solanezumab is not effective in preventing Alzheimer’s disease
March 14th, 2023
Katie Seidenberg and R. Scott Turner Eli Lilly and collaborators released the topline results of the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) Study March…
Lecanumab (LeqembiTM) FDA-approved for individuals with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s disease (AD) – collectively called early AD R. Scott Turner
January 20th, 2023
R. Scott Turner A breakthrough, finally! Leqembi is the first disease-modifying treatment for individuals with MCI and mild AD with solid evidence of effectiveness. Thus, Leqembi (previously…
MDP in the News
October 11th, 2022
The Memory Disorders Program’s own Clinical Trial Manager, Angelica Forero, was interviewed about a groundbreaking clinical trial at Georgetown using ‘nicotine’ to end memory loss. See the full…
Allegations of fraud in Alzheimer’s disease research- death of the amyloid hypothesis?
August 1st, 2022
R. Scott Turner, PhD, MD Recent reports of fraud in Alzheimer’s disease (AD) research have raised major concerns. Some of the figures in a highly-cited paper (using animal models of…
POCUS Tips and Tricks for Beginners with Dr. Tiffany FongMar. 21
Georgetown Lombardi Visiting Professor and Grand Rounds Lecture Series Featuring Adrian Lee, PhDMar. 24
Open Access Workshop from DMLMar. 28
Bhussry Seminar Series – “Synthetic Embryology for Building Human Embryo and Organ Models”Mar. 28
Building D, Suite 177
4000 Reservoir Road, N.W.,
Washington DC 20057
MGUH Department of Neurology
Pasquerilla Health Center (PHC), 7th Floor
3800 Reservoir Road, NW
Washington D.C. 20007
